Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3111MR)

This product GTTS-WQ3111MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3111MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8383MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ6625MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ10006MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ144MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ8761MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ12806MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ1785MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ15183MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW